MGP INGREDIENTS INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that MGP INGREDIENTS INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $19.78M | Feb 27, 2019 |
| FY2018 | Dec 31, 2017 | $22.87M | Feb 27, 2019 |
| FY2018 | Dec 31, 2016 | $22.42M | Feb 27, 2019 |
| FY2017 | Dec 31, 2015 | $18.77M | Mar 1, 2018 |
| FY2016 | Dec 31, 2014 | $16.31M | Mar 8, 2017 |
| FY2015 | Dec 31, 2013 | $12.67M | Mar 17, 2016 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $536.38M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $703.63M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $836.52M | Feb 25, 2026 |
| FY2022 | Dec 31, 2022 | $191.00M | Feb 23, 2023 |
| FY2022 | Sep 30, 2022 | $201.15M | Feb 23, 2023 |
| FY2022 | Jun 30, 2022 | $194.98M | Feb 23, 2023 |
| FY2022 | Mar 31, 2022 | $195.24M | Feb 23, 2023 |
| FY2022 | Dec 31, 2021 | $166.85M | Feb 23, 2023 |
| FY2022 | Sep 30, 2021 | $176.61M | Feb 23, 2023 |
| FY2022 | Jun 30, 2021 | $174.94M | Feb 23, 2023 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $88.19M | Mar 1, 2018 |
| FY2017 | Sep 30, 2017 | $86.33M | Mar 1, 2018 |
| FY2017 | Jun 30, 2017 | $85.75M | Mar 1, 2018 |
| FY2017 | Mar 31, 2017 | $87.17M | Mar 1, 2018 |
| FY2017 | Dec 31, 2016 | $81.15M | Mar 1, 2018 |
| FY2017 | Sep 30, 2016 | $79.89M | Mar 1, 2018 |
| FY2017 | Jun 30, 2016 | $80.39M | Mar 1, 2018 |
| FY2017 | Mar 31, 2016 | $76.84M | Mar 1, 2018 |
| FY2017 | Dec 31, 2015 | $327.60M | Mar 1, 2018 |
| FY2011 | Dec 31, 2011 | $146.48M | Mar 13, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $199.41M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $286.32M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $304.71M | Feb 25, 2026 |
| FY2022 | Dec 31, 2022 | $63.21M | Feb 23, 2023 |
| FY2022 | Sep 30, 2022 | $59.05M | Feb 23, 2023 |
| FY2022 | Jun 30, 2022 | $59.22M | Feb 23, 2023 |
| FY2022 | Mar 31, 2022 | $71.82M | Feb 23, 2023 |
| FY2022 | Dec 31, 2021 | $52.75M | Feb 23, 2023 |
| FY2022 | Sep 30, 2021 | $57.09M | Feb 23, 2023 |
| FY2022 | Jun 30, 2021 | $56.83M | Feb 23, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($107.81M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $34.66M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $107.48M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $109.46M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $91.31M | Feb 22, 2024 |
| FY2020 | Dec 31, 2020 | $11.63M | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $10.38M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $8.49M | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | $9.84M | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $12.95M | Feb 25, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($94.62M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $74.43M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $148.61M | Feb 25, 2026 |
| FY2022 | Dec 31, 2022 | $29.72M | Feb 23, 2023 |
| FY2022 | Sep 30, 2022 | $33.86M | Feb 23, 2023 |
| FY2022 | Jun 30, 2022 | $35.31M | Feb 23, 2023 |
| FY2022 | Mar 31, 2022 | $50.08M | Feb 23, 2023 |
| FY2022 | Dec 31, 2021 | $45.32M | Feb 23, 2023 |
| FY2022 | Sep 30, 2021 | $32.88M | Feb 23, 2023 |
| FY2022 | Jun 30, 2021 | $27.66M | Feb 23, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $916.0K | Mar 8, 2017 |
| FY2016 | Dec 31, 2015 | $748.0K | Mar 8, 2017 |
| FY2016 | Dec 31, 2014 | $1.62M | Mar 8, 2017 |
| FY2015 | Dec 31, 2013 | $2.47M | Mar 17, 2016 |
| FY2013 | Dec 31, 2012 | $2.34M | Mar 13, 2014 |
| FY2012 | Dec 31, 2011 | $954.0K | Mar 12, 2013 |
| FY2012 | Jun 30, 2011 | $1.43M | Mar 12, 2013 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $84.82M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $81.39M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $91.40M | Feb 25, 2026 |
| FY2022 | Dec 31, 2022 | $22.63M | Feb 23, 2023 |
| FY2022 | Sep 30, 2022 | $17.91M | Feb 23, 2023 |
| FY2022 | Jun 30, 2022 | $17.85M | Feb 23, 2023 |
| FY2022 | Mar 31, 2022 | $16.24M | Feb 23, 2023 |
| FY2022 | Dec 31, 2021 | $17.55M | Feb 23, 2023 |
| FY2022 | Sep 30, 2021 | $18.54M | Feb 23, 2023 |
| FY2022 | Jun 30, 2021 | $25.79M | Feb 23, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $121.53M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $102.28M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $83.78M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $88.94M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $88.26M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $53.26M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $19.72M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $33.48M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $33.47M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $19.72M | Feb 27, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.49M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $71.18M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $55.27M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $45.32M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $47.39M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $19.70M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $16.73M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $31.05M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $21.06M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $17.92M | Feb 27, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.24B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $1.41B | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $1.39B | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $1.16B | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $1.04B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $366.58M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $322.60M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $277.89M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $240.33M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $225.34M | Mar 1, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $519.07M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $573.24M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $543.28M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $412.57M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $397.20M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $104.05M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $91.55M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $76.45M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $71.60M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $79.04M | Mar 1, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $718.44M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $834.17M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $850.49M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $746.72M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $644.76M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $262.53M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $231.04M | Feb 25, 2021 |
| FY2020 | Dec 31, 2018 | $201.44M | Feb 25, 2021 |
| FY2020 | Dec 31, 2017 | $168.73M | Feb 25, 2021 |
| FY2019 | Dec 31, 2016 | $146.29M | Feb 26, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $115.67M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $247.79M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $321.54M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $226.29M | Feb 26, 2025 |
| FY2022 | Dec 31, 2021 | $226.29M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $2.74M | Feb 24, 2022 |
| FY2017 | Dec 31, 2017 | $1.50M | Mar 1, 2018 |
| FY2017 | Dec 31, 2016 | $1.50M | Mar 1, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $445.74M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $563.93M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $539.88M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $443.06M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $344.24M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $262.94M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $230.78M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $198.91M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $167.13M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $142.65M | Mar 1, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.46M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $25.27M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $18.39M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $47.89M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $21.57M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $21.66M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $3.31M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $5.03M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $3.08M | Feb 27, 2019 |
| FY2018 | Dec 31, 2016 | $1.57M | Feb 27, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $260.05M | Feb 25, 2026 |
| FY2024 | Dec 31, 2024 | $329.45M | Feb 26, 2025 |
| FY2023 | Dec 31, 2023 | $293.85M | Feb 22, 2024 |
| FY2022 | Dec 31, 2022 | $236.45M | Feb 23, 2023 |
| FY2021 | Dec 31, 2021 | $239.85M | Feb 24, 2022 |
| FY2020 | Dec 31, 2020 | $40.00M | Feb 25, 2021 |
| FY2019 | Dec 31, 2019 | $41.51M | Feb 26, 2020 |
| FY2018 | Dec 31, 2018 | $32.59M | Feb 27, 2019 |
| FY2017 | Dec 31, 2017 | $25.26M | Mar 1, 2018 |
| FY2016 | Dec 31, 2016 | $36.58M | Mar 8, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | 4 | Feb 25, 2026 |
| FY2022 | Dec 31, 2022 | 1 | Feb 23, 2023 |
| FY2022 | Sep 30, 2022 | 1 | Feb 23, 2023 |
| FY2022 | Jun 30, 2022 | 1 | Feb 23, 2023 |
| FY2022 | Mar 31, 2022 | 1 | Feb 23, 2023 |
| FY2022 | Dec 31, 2021 | 1 | Feb 23, 2023 |
| FY2022 | Sep 30, 2021 | 1 | Feb 23, 2023 |
| FY2022 | Jun 30, 2021 | 0 | Feb 23, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | 4 | Feb 25, 2026 |
| FY2022 | Dec 31, 2022 | 1 | Feb 23, 2023 |
| FY2022 | Sep 30, 2022 | 1 | Feb 23, 2023 |
| FY2022 | Jun 30, 2022 | 1 | Feb 23, 2023 |
| FY2022 | Mar 31, 2022 | 1 | Feb 23, 2023 |
| FY2022 | Dec 31, 2021 | 1 | Feb 23, 2023 |
| FY2022 | Sep 30, 2021 | 1 | Feb 23, 2023 |
| FY2022 | Jun 30, 2021 | 0 | Feb 23, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 21.29M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 21.19M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | 22.02M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | 21.99M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | 21.96M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | 16.92M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | 17.03M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 16.86M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | 16.80M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | 16.66M | Mar 1, 2018 |